Abstract
β-Elemene, an anticancer agent, was isolated from the traditional Chinese medicine plant, curcuma aromatica. In this study, we investigated the synergistic antitumor effect of β-elemene and etoposide phosphate (VP-16) in A549 non-small cell lung carcinoma cells. The cells were treated with β-elemene (20 or 50 µg/ml), VP-16 (15 µg/ml) or the combination of both for 24 h. Compared to the treatment with β-elemene or VP-16 alone, an increased antitumor activity was observed with the combination of both, which was mediated by the cleavage of PARP, the up-regulation of Bax, p53 and p21, and the suppression of cyclin D1. These results suggest that the combination of β-elemene and VP-16 may be a promising therapeutic option for lung cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Agents / toxicity*
-
Apoptosis / drug effects*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / metabolism
-
Cell Cycle Checkpoints / drug effects*
-
Cell Line, Tumor
-
Curcuma / chemistry
-
Cyclin D1 / metabolism
-
Cyclin-Dependent Kinase Inhibitor p21 / metabolism
-
Etoposide / analogs & derivatives*
-
Etoposide / therapeutic use
-
Etoposide / toxicity
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / metabolism
-
Organophosphorus Compounds / therapeutic use
-
Organophosphorus Compounds / toxicity*
-
Poly(ADP-ribose) Polymerases / metabolism
-
Sesquiterpenes / therapeutic use
-
Sesquiterpenes / toxicity*
-
Tumor Suppressor Protein p53 / metabolism
-
bcl-2-Associated X Protein / metabolism
Substances
-
Antineoplastic Agents
-
Cyclin-Dependent Kinase Inhibitor p21
-
Organophosphorus Compounds
-
Sesquiterpenes
-
Tumor Suppressor Protein p53
-
bcl-2-Associated X Protein
-
beta-elemene
-
Cyclin D1
-
etoposide phosphate
-
Etoposide
-
Poly(ADP-ribose) Polymerases